Full Breakdown
FDA Approves Merck Oral PCSK9 Drug as Kalshi Introduces Biotech Betting Markets
7/16/2026, 8:56:28 PM
Merck’s Oral PCSK9 Inhibitor Receives FDA Clearance
On July 16 2026, the U.S. Food and Drug Administration granted approval for Merck’s oral PCSK9 inhibitor, marking the first FDA endorsement of an oral therapy in this drug class. The decision expands treatment options for patients requiring cholesterol-lowering medication, which traditionally has relied on injectable PCSK9 inhibitors.
Kalshi Unveils Biopharma Prediction Markets
The same day, prediction-market platform Kalshi announced the launch of new betting markets focused on biopharma outcomes. Partnering with AppliedXL—a technology firm that monitors and forecasts clinical-trial results—Kalshi will initially offer a limited set of markets covering clinical-trial endpoints and regulatory approvals. The rollout is intended to provide participants with a mechanism to wager on the success of biotech developments, including FDA decisions.
Context and Potential Impact
Kalshi’s entry into biotech betting follows a broader trend of financial platforms seeking to monetize scientific uncertainty. By allowing wagers on trial outcomes, the markets could aggregate diverse expert opinions, potentially offering real-time signals to investors and researchers. Meanwhile, Merck’s oral PCSK9 approval reflects ongoing innovation aimed at improving patient adherence compared with injectable alternatives. Together, these developments illustrate a convergence of pharmaceutical advancement and novel data-driven market mechanisms.
Official Statements & Responses
Kalshi’s announcement described the partnership with AppliedXL as a “small number of markets selected alongside partner AppliedXL, a tech company that already monitors and predicts clinical trial outcomes.” The FDA’s approval notice confirmed Merck’s oral PCSK9 drug met the agency’s safety and efficacy standards, enabling its commercial launch.
